AnodyneWiki

Modafinil

Modafinil
Modafinil
Salts
[]
Modafinil hydrochloride
Modafinil hydrochloride
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass273.40 g/mol [1]
AppearanceWhite to off-white crystalline powder [1]
Melting point164-166 °C [1]
SolubilitySlightly soluble [1]
Predicted LogP1.7 [1]
Structural Identifiers
[]
Molecular formulaC15H15NO2S
IUPAC name2-benzhydrylsulfinylacetamide
SMILESC1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N
InChIInChI=1S/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)
InChIKeyYFGHCGITMMYXAQ-UHFFFAOYSA-N
CAS number68693-11-8
UNIIR3UK8X3U3D
PubChem CID4236
Pharmacokinetics[]
Onset2–4 hour (peak)
Elimination half-lifeModafinil: 12–15 hour, Armodafinil: 10–17 hour, Esmodafinil: 3–5 hour[3]
Duration of action11.5 hour
MetabolismLiver (amide hydrolysis, S-oxidation, aromatic ring hydroxylation, glucuronide conjugation; CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5 involved)
ExcretionUrine: 80% (≤10% as modafinil, 35–51 % as modafinil acid), Feces: 1.0%
Routes of administrationOral (tablets)
Dependence liabilityRelatively low
Addiction liabilityLow

Modafinil (also known as Provigil, Modiodal, 2-(Benzhydrylsulfinyl)acetamide, 2-[(diphenylmethyl)sulfinyl]acetamide, modaphonil, Modafinilo, Crl 40476, Modafinilum, Modafinil civ or R Modafinil) is a eugeroic substance.

Chemistry

Salts []

Modafinil is typically found in the form of its hydrochloride salt.

 []

Modafinil is a racemic mixture of the (optical activity ( + / - )).

Modafinil matches Lipinski's rule of five.

There are currently 5 reagent-interactions on

ReagentColor changeDescription
Marquisyellow/orange > brown
Meckeorange > brown
Mandelinbrownish red
Liebermanndarkening orange
Froehdedeep orange / red

Pharmacology

Mechanism of action []

The exact mechanism of action is unclear, although <i>in vitro</i> studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA. Modafinil is thought to have less potential for abuse than other stimulants due to the absence of any significant euphoric or pleasurable effects. It is possible that modafinil acts by a synergistic combination of mechanisms including direct inhibition of dopamine reuptake, indirect inhibition of noradrenalin reuptake in the VLPO and orexin activation. Modafinil has partial alpha 1B-adrenergic agonist effects by directly stimulating the receptors. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

metabolism / induction / inhibition416 (6 contraindicated)
inhibition116 (1 contraindicated)
inhibition60 (1 contraindicated)
induction33
induction30

Medical side effects []

197 side effects listed on drug labels in (modafinil).

  • Nausea
  • Dizziness
  • Syncope
  • Insomnia
  • Anxiety
  • Diarrhoea
  • Loose stools
  • Dry mouth
  • Depression
  • Depression aggravated
  • Anxiety depression
  • Dyspepsia
  • Dermatitis
  • Rash
  • Asthenia
  • Fatigue
  • Headache
  • Palpitations
  • Abdominal pain upper
  • Decreased appetite
  • Conjunctivitis
  • Constipation
  • Dermatitis contact
  • Dyspnoea
  • Body temperature increased
  • Seasonal allergy
  • Rhinitis seasonal
  • Hyperhidrosis
  • Sweating
  • Nervousness
  • Tension
  • Pain
  • Paraesthesia
  • Polyuria
  • Urine output increased
  • Pruritus
  • Tachycardia
  • Thirst
  • Tremor
  • Vomiting
  • Agitation
  • Hyperkinesia
  • Migraine
  • Gamma-glutamyltransferase increased
  • Disturbance in attention
  • Depressed mood
  • Influenza like illness
  • Pollakiuria
  • Muscle twitching
  • Ataxia
  • Cystitis
  • Bladder pain
  • Cystitis noninfective
  • Hearing impaired
  • Cardiac arrest
  • Leukocytosis
  • Personality disorder
  • Hyperacusis
  • Pain in jaw
  • Erectile dysfunction
  • Photosensitivity reaction
  • Muscular weakness
  • Abdominal pain
  • Gastrointestinal pain
  • Aggression
  • Agranulocytosis
  • Anaphylactic shock
  • Anaphylactoid reaction
  • Angioedema
  • Arrhythmia
  • Mental disorder
  • Chest pain
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Connective tissue disorder
  • Delusion
  • Drug eruption
  • Dyskinesia
  • Orofacial dyskinesia
  • Eczema
  • Oedema
  • Eosinophilia
  • Toxic epidermal necrolysis
  • Erythema multiforme
  • Stevens-Johnson syndrome
  • Gastrointestinal disorder
  • Hallucination
  • Cardiac disorder
  • Hypersensitivity
  • Hypertension
  • Immune system disorder
  • Irritability
  • Nervous system disorder
  • Psychotic disorder
  • Convulsion
  • Suicide attempt
  • Urethral disorder
  • Urinary tract disorder
  • Urticaria
  • Angiopathy
  • Weight increased
  • Weight decreased
  • Myocardial ischaemia
  • Skin disorder
  • Discomfort
  • Ill-defined disorder
  • Thinking abnormal
  • Mental disability
  • Condition aggravated
  • Mania
  • Suicidal ideation
  • Blood pressure increased
  • Electrocardiogram abnormal
  • Urine odour abnormal
  • Tardive dyskinesia
  • Albuminuria
  • Amblyopia
  • Amnesia
  • Anaemia
  • Arthralgia
  • Musculoskeletal discomfort
  • Myalgia
  • Arthritis
  • Asthma
  • Back pain
  • Bronchitis
  • Cataplexy
  • Neck pain
  • Infection
  • Cough
  • Cough increased
  • Libido decreased
  • Disturbance in sexual arousal
  • Somnolence
  • Dysgeusia
  • Dysmenorrhoea
  • Ear disorder
  • Ear pain
  • Ecchymosis
  • Epistaxis
  • Flatulence
  • Gastroenteritis
  • Gingivitis
  • Haematuria
  • Herpes simplex
  • Hyperglycaemia
  • Hypotension
  • Body temperature decreased
  • Hypothermia
  • Influenza
  • Arthropathy
  • Osteoarthritis
  • Muscle spasms
  • Lung disorder
  • Mediastinal disorder
  • Hypertonia
  • Obesity
  • Pancytopenia
  • Tooth abscess
  • Pharyngitis
  • Pneumonia
  • Psoriasis
  • Pyuria
  • Rhinitis
  • Sinusitis
  • Shock
  • Loss of consciousness
  • Tooth disorder
  • Urinary tract infection
  • Vasodilation procedure
  • Vertigo
  • Viral infection
  • Urinary retention
  • Chills
  • Mood swings
  • Affect lability
  • Oedema peripheral
  • Hepatic function abnormal
  • Stomatitis
  • Mouth ulceration
  • Musculoskeletal stiffness
  • Nuchal rigidity
  • Ventricular extrasystoles
  • Injury
  • Eye pain
  • Aspartate aminotransferase increased
  • Dry skin
  • Malnutrition
  • Increased appetite
  • Psychiatric symptom
  • Urine abnormality
  • Urine analysis abnormal
  • Hepatic enzyme increased
  • Bradycardia
  • Ejaculation disorder
  • Visual impairment

Indications

  • Apnoea
  • Cataplexy
  • Dyskinesia
  • Excessive daytime sleepiness
  • Fatigue
  • Hypersomnia
  • Hypopnea syndrome
  • Narcolepsy
  • Obstructive sleep apnea syndrome
  • Sleep disorder
  • Wakefulness

Subjective effects []

0xea / Modafinil []
Routes:
  • Oral (100 - 400mg)
Effects:Notes:
  • effects not notable
alina / Modafinil []
Routes:
  • Oral (50 - 100mg)
bonzi / Modafinil []
Routes:
  • Oral (100 - 200mg)
nervewing / Modafinil []
ninerik / Modafinil []
Routes:
  • Oral (100 - 400mg)
Classes:Source:
  • DNM
  • Pharmacy
Effects:Notes:
  • Yummy wakefulness

Experience reports

Erowid

There are currently 30 experience reports involving modafinil on : []

Reddit

There are currently 6 trip reports involving modafinil on : []

 []

  • Australia: Modafinil is a Schedule 4.
  • Brazil: Modafinil is a B1.[4]
  • Canada: Modafinil is Prescription only.[5]
  • United Kingdom: Modafinil is Prescription only.
  • United States: Modafinil is a Schedule IV under the "Controlled Substances Act".
  • Other: Modafinil is a SE: Förteckning IV.[6]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 4236, Modafinil. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4236
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Modafinil. UNII: R3UK8X3U3D. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/R3UK8X3U3D
  3. Niemegeers P, Maudens KE, Morrens M, Patteet L, Joos L, Neels H, Sabbe BG. Pharmacokinetic evaluation of armodafinil for the treatment of bipolar depression. Expert Opin Drug Metab Toxicol. September 2012; 8(9):1189–1197. PMID 22803602. https://doi.org/10.1517/17425255.2012.708338
  4. RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. March 31, 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  5. Modafinil Product information. Health Canada. April 25, 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=63139
  6. Modafinil Orion, Tablett 100 mg. FASS. 6 October 2023. https://fass.se/health/product/20141031000035/fass-text

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 10:21:53
drugsprook2026-11-20 10:21:49
erowidok2026-11-20 10:21:51
gsrsok2026-11-20 10:21:50
hmdbmissing (hmdb.ca refused automated access to HMDB0014883)2026-11-20 10:21:49
keggok2026-11-20 10:21:51
pubchemok2026-11-20 10:21:47
redditok2026-11-20 10:21:49
siderok2026-11-20 10:21:49
structureok2026-11-20 10:21:49
wikipediaok2026-11-20 10:21:49